Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Stock Options of Inovio Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2021.

04/21/2021 EDT

Certain Stock Options of Inovio Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2021. These Stock Options will be under lockup for 91 days starting from 20-JAN-2021 to 21-APR-2021. Details: Executive officers and directors have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 90 days after the date of this prospectus supplement without first obtaining the written consent of BofA Securities, Inc. and Jefferies LLC.


ę S&P Capital IQ 2021
All news about INOVIO PHARMACEUTICALS, INC.
09/10INOVIO PHARMACEUTICALS : BofA Securities Downgrades Inovio Pharmaceuticals to Underperform..
MT
09/01INOVIO PHARMACEUTICALS : to Present at Upcoming Investor Conferences in September
PR
08/26INOVIO PHARMACEUTICALS : Receives Authorization From Brazil Regulator to Start Phase 3 Tri..
MT
08/26INOVIO PHARMACEUTICALS : Receives Authorization to Conduct Phase 3 Efficacy Trial of its C..
PR
08/26INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vac..
CI
08/09INOVIO PHARMACEUTICALS : focused on launching global COVID-19 vaccine trial next month - C..
RE
08/09INOVIO PHARMACEUTICALS : focused on launching global COVID-19 vaccine trial next month - C..
RE
08/09INOVIO : Q2 Earnings Snapshot
AQ
08/09INOVIO PHARMACEUTICALS : Reports Narrower Q2 Loss on Higher Revenue
MT
08/09INOVIO PHARMACEUTICALS : Earnings Flash (INO) INOVIO PHARMACEUTICALS Posts Q2 Revenue $272..
MT
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 4,71 M - -
Net income 2021 -272 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,99x
Yield 2021 -
Capitalization 1 639 M 1 639 M -
Capi. / Sales 2021 348x
Capi. / Sales 2022 16,6x
Nbr of Employees 262
Free-Float 98,3%
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 7,79 $
Average target price 13,22 $
Spread / Average Target 69,7%
EPS Revisions
Managers and Directors
J. Joseph Kim President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Kate E. Broderick Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
INOVIO PHARMACEUTICALS, INC.-11.98%1 639
MODERNA, INC.305.22%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.41.30%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-9.18%28 939